|
| Schizophrenia | Controls | p valueb | ||
| Sample size | 20 | 20 |
| ||
| Gender (% female) | 15.00 | 15.00 | 1.00 | ||
| Age at time of testing (years) | 30.60 | 30.70 | 0.97 | ||
| Educational levela | 4.15 | 4.35 | 0.57 | ||
| Age at disease onset (years) | 26.45 |
|
| ||
| Disease duration (years) | 4.50 |
|
| ||
| PANSS total | 53.25 |
|
| ||
| PANSS positive | 11.75 |
|
| ||
| PANSS negative | 13.00 |
|
| ||
| MADRS | 11.90 |
|
| ||
| CGI | 4.20 |
|
| ||
| Medication (absolute frequency) | Neuroleptics | Atypical | 15 |
|
|
| Atypical and typical | 5 |
|
| ||
| Anti-depressants | Tricyclics | 1 |
|
| |
| Tetracyclics | 2 |
|
| ||
| SSRI | 4 |
|
| ||
| SSNRI | 4 |
|
| ||
| Benzodiazepine | 2 |
|
| ||
| Anticholinergics (e.g. Akineton) | 5 |
|
| ||
| β-blockers | 3 |
|
| ||
| Hypnotics | 1 |
|
| ||
| CPZ-equivalent total daily dosis (mg) | 842.80 |
|
| ||